Number needed to treat is incorrect without proper time-related considerations

被引:61
作者
Suissa, Daniel [2 ]
Brassard, Paul [1 ,3 ]
Smiechowski, Brielan [1 ,3 ]
Suissa, Samy [1 ,3 ]
机构
[1] Jewish Gen Hosp, Lady Davis Inst, Ctr Clin Epidemiol, Montreal, PQ H3T 1E2, Canada
[2] Ctr Hosp Univ Monreal, Hop Notre Dame, Quebec City, PQ, Canada
[3] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada
基金
加拿大健康研究院;
关键词
Biostatistics; Epidemiology; Impact measure; Methods; Observational studies; Randomized controlled trials; PLACEBO-CONTROLLED TRIAL; PRIMARY PREVENTION; DISEASE; THERAPY; RISK; HYPERTENSION; FRACTURE; CANCER; EVENT; BLIND;
D O I
10.1016/j.jclinepi.2011.04.009
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The number needed to treat (NNT) is a simple measure of a treatment's impact, increasingly reported in randomized trials and observational studies. Its calculation in studies involving varying follow-up times or recurrent outcomes has been criticized. We discuss the NNT in these contexts, illustrating using several Published studies. The computation of the NNT is founded on the cumulative incidence of the outcome. Instead, several published studies use simple proportions that do not account for varying follow-up times, or use incidence rates per person-time. We show that these approaches can lead to erroneous values of the NNT and misleading interpretations. For example, after converting the incidence rate to a cumulative incidence, we show that a trial reporting a NNT of 4 "to prevent one exacerbation in 1 year" should have reported a NNT of 9. A survey of all papers reporting NNT, published in four major medical journals in 2009, found that 6 out of all 10 papers involving varying follow-up times did not correctly estimate the NNT. As the "number needed to treat" becomes increasingly used in complex studies and in the comparative effectiveness of therapies, its accurate estimation and interpretation become crucial to avoid erroneous clinical and public health decisions. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:42 / 46
页数:5
相关论文
共 27 条
[1]   Exaggeration of treatment benefits using the "event-based" number needed to treat [J].
Aaron, Shawn D. ;
Fergusson, Dean A. .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2008, 179 (07) :669-671
[2]   Calculating the number needed to treat for trials where the outcome is time to an event [J].
Altman, DG ;
Andersen, PK .
BRITISH MEDICAL JOURNAL, 1999, 319 (7223) :1492-1495
[3]   Treatment of hypertension in patients 80 years of age or older [J].
Beckett, Nigel S. ;
Peters, Ruth ;
Fletcher, Astrid E. ;
Staessen, Jan A. ;
Liu, Lisheng ;
Dumitrascu, Dan ;
Stoyanovsky, Vassil ;
Antikainen, Riitta L. ;
Nikitin, Yuri ;
Anderson, Craig ;
Belhani, Alli ;
Forette, Francoise ;
Rajkumar, Chakravarthi ;
Thijs, Lutgarde ;
Banya, Winston ;
Bulpitt, Christopher J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (18) :1887-1898
[4]   Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia [J].
Bucaneve, G ;
Micozzi, A ;
Menichetti, F ;
Martino, P ;
Dionisi, MS ;
Martinelli, G ;
Allione, B ;
D'Antonio, D ;
Buelli, M ;
Nosari, AM ;
Cilloni, D ;
Zuffa, E ;
Cantaffa, R ;
Specchia, G ;
Amadori, S ;
Fabbiano, F ;
Deliliers, GL ;
Lauria, F ;
Foà, R ;
Del Favero, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (10) :977-987
[5]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[6]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[7]  
Collett D, 1994, MODELLING SURVIVAL D
[8]   Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial [J].
Comi, G. ;
Martinelli, V. ;
Rodegher, M. ;
Moiola, L. ;
Bajenaru, O. ;
Carra, A. ;
Elovaara, I. ;
Fazekas, F. ;
Hartung, H. P. ;
Hillert, J. ;
King, J. ;
Komoly, S. ;
Lubetzki, C. ;
Montalban, X. ;
Myhr, K. M. ;
Ravnborg, M. ;
Rieckmann, P. ;
Wynn, D. ;
Young, C. ;
Filippi, M. .
LANCET, 2009, 374 (9700) :1503-1511
[9]   Once-daily valacyclovir to reduce the risk of transmission of genital herpes [J].
Corey, L ;
Wald, A ;
Patel, R ;
Sacks, SL ;
Tyring, SK ;
Warren, T ;
Douglas, JM ;
Paavonen, J ;
Morrow, RA ;
Beutner, KR ;
Stratchounsky, LS ;
Mertz, G ;
Keene, ON ;
Watson, HA ;
Tait, D ;
Vargas-Cortes, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (01) :11-20
[10]   Diet and Lifestyle Risk Factors Associated With Incident Hypertension in Women [J].
Forman, John P. ;
Stampfer, Meir J. ;
Curhan, Gary C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (04) :401-411